The impact of coronavirus disease 2019 on genitourinary and prostate cancer care and clinical trials: a qualitative exploration of the Australian and New Zealand experience.

Abstract: Purpose: This qualitative study aimed to understand the impact of the coronavirus disease 2019 pandemic from March to November 2020 on healthcare delivery and clinical trials for genitourinary (GU) cancers in Australia. Methods: Annually a pre‐conference workshop is hosted by the Australian New Zealand Urogenital and Prostate Cancer Trials Group for supportive care health professionals. In November 2020, those that selected to attend were invited to participate in a focus group. Workshop and focus group discussions were recorded and transcripts were analyzed thematically. Results: Seventy‐two individuals involved in GU cancer care and clinical trials took part. Participants described negative changes to GU cancer care and clinical trials from the pandemic due to reduced clinical services and increased wait times. Trial recruitment was paused temporarily during lockdowns, and standard treatment protocols were used to limit hospital visits. Trial process changes included electronic capture of informed consent, home delivery of oral medications, and delegations of assessments. These changes increased administrative activity for clinical trial teams and Human Research Ethics Committees. A transition to telehealth enabled continuity of service delivery and trials but reduced the opportunity for face‐to‐face patient consultations with increasing concern about the failure to detect supportive care needs. Conclusion: The pandemic has prompted a critical review of service delivery and clinical trials for people with GU cancers

Does the delivery of diagnostic news affect the likelihood of whether or not patients ask questions about the results? A conversation analytic study

The file attached to this record is the author's final peer reviewed version. The Publisher's final version can be found by following the DOI link.This paper was produced following a collaboration between researchers at Imperial College London, University of Leicester and De Montfort University

Development and piloting of a brain tumour-specific question prompt list

The objective of this research was to develop a question prompt list aimed at increasing question asking and reducing the unmet information needs of adults with primary brain tumours, and to pilot the question prompt list to determine its suitability for the intended population. Thematic analysis of existing resources was used to create a draft which was refined via interviews with 12 brain tumour patients and six relatives, readability testing and review by health professionals. A non-randomised before–after pilot study with 20 brain tumour patients was used to assess the acceptability and usefulness of the question prompt list, compared with a ‘standard brochure’, and the feasibility of evaluation strategies. The question prompt list developed covered seven main topics (diagnosis, prognosis, symptoms and changes, treatment, support, after treatment finishes and the health professional team). Pilot study participants provided with the question prompt list agreed that it was helpful (7/7), contained questions that were useful to them (7/7) and prompted them to ask their medical oncologist questions (5/7). The question prompt list is acceptable to patients and contains questions relevant to them. Research is now needed to assess its effectiveness in increasing question asking and reducing unmet information needs

The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group - a new co-operative cancer trials group in genitourinary oncology

Full Tex

The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group : a new co-operative cancer trials group in genitourinary oncology

The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group was formed in 2008 as the first comprehensive cooperative trials group for genitourinary oncology in Australia and New Zealand, by the merger of the Australian Prostate and Urogenital cancer Group (APUG) and the Australian and New Zealand Germ Cell Trials Group (ANZGCTG), with funding from The Victorian Cancer Agency and subsequently from Cancer Australia. ANZUP’s stated mission is to conduct clinical trial research to improve treatment of bladder, kidney, testicular and prostate cancers (http://www.anzup.org.au, accessed on 12 February 2015). To this end, it aims to bring together all the professional disciplines and groups involved in researching and treating urogenital cancers

E-TC: Development and pilot testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancer

Abstract not available

e-TC : Development and pilot testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancer

e-TC is an online intervention designed to address common psychosocial concerns of testicular cancer survivors. It aims to reduce anxiety, depression and fear of cancer recurrence by providing evidence-based information and psychological intervention. This paper details the development and pilot testing of e-TC. During pilot testing, 25 men (with varying psychological profiles) who had completed treatment for testicular cancer, 6 months to 5 years ago (which had not recurred), used e-TC over a 10-week period and provided quantitative and qualitative feedback on the feasibility and acceptability of the programme. Six men also completed a qualitative interview to provide detailed feedback on their experiences using e-TC. Fourteen men (56%) completed at least 80% of the programme. Participants reported a high level of satisfaction with the programme. Men's limited time was a barrier to programme use and completion, and participants suggested that men with a more recent diagnosis and a higher level of distress may be more likely to engage with the programme. e-TC appears to be a feasible and acceptable online intervention for survivors of testicular cancer. Findings from this study are currently being used to refine e-TC and guide the design of a larger efficacy study. © 2017 John Wiley & Sons Lt